Free Trial

ADC Therapeutics (ADCT) Stock Forecast & Price Target

$3.29
+0.24 (+7.87%)
(As of 10/4/2024 08:49 PM ET)

ADC Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
4

Based on 5 Wall Street analysts who have issued ratings for ADC Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for ADCT.

Consensus Price Target

$9.00
173.56% Upside
According to the 5 analysts' twelve-month price targets for ADC Therapeutics, the average price target is $9.00. The highest price target for ADCT is $11.00, while the lowest price target for ADCT is $8.00. The average price target represents a forecasted upside of 173.56% from the current price of $3.29.
Get the Latest News and Ratings for ADCT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ADC Therapeutics and its competitors.

Sign Up

ADCT Analyst Ratings Over Time

TypeCurrent Forecast
10/8/23 to 10/7/24
1 Month Ago
9/8/23 to 9/7/24
3 Months Ago
7/10/23 to 7/9/24
1 Year Ago
10/8/22 to 10/8/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.00$9.00$7.25$8.20
Forecasted Upside173.56% Upside233.33% Upside128.71% Upside876.19% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

ADCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ADCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ADC Therapeutics Stock vs. The Competition

TypeADC TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.79
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside173.56% Upside10,601.72% Upside7.04% Upside
News Sentiment Rating
Neutral News

See Recent ADCT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/8/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+191.44%
8/7/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00+185.71%
5/30/2024Cantor Fitzgerald
3 of 5 stars
E. Schmidt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
4/5/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
11/9/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform
8/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral
7/11/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$5.00 ➝ $2.00+8.11%
4/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform
12/6/2022Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Quibria
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00+249.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:37 AM ET.


ADCT Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for ADC Therapeutics is $9.00, with a high forecast of $11.00 and a low forecast of $8.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADCT shares.

According to analysts, ADC Therapeutics's stock has a predicted upside of 173.56% based on their 12-month stock forecasts.

ADC Therapeutics has been rated by research analysts at HC Wainwright, and Royal Bank of Canada in the past 90 days.

Analysts like ADC Therapeutics more than other "medical" companies. The consensus rating score for ADC Therapeutics is 2.80 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ADCT compares to other companies.


This page (NYSE:ADCT) was last updated on 10/7/2024 by MarketBeat.com Staff
From Our Partners